⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15074897 | 0.76 | — | — | |
| SCHEMBL13893139 | 0.73 | — | — | |
| SCHEMBL8104886 | 0.73 | — | — | |
| SCHEMBL17937333 | 0.73 | — | — | |
| SCHEMBL13075722 | 0.73 | — | — | |
| SCHEMBL21093502 | 0.73 | — | — | |
| SCHEMBL27245 | 0.72 | — | — | |
| SCHEMBL3261400 | 0.70 | — | — | |
| SCHEMBL14204503 | 0.70 | — | — | |
| SCHEMBL776535 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| EP-4353235-A2 | NLRP3 MODULATORS | Innate Tumor Immunity, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| US-11806404-B2 | Site specific homogeneous with KSP inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-11-07 | — | — | US | disclosed |
| WO-2023156510-A1 | METHOD FOR DETECTING AN ANALYTE OF INTEREST IN A SAMPLE | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023148129-A1 | IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | disclosed |
| EP-3794002-B1 | COMPOUNDS | ENTERPRISE THERAPEUTICS LTD (GB) | 2023-08-02 | — | — | EP | disclosed |
| CN-114667285-A | Antiviral pyrazolopyridinone compounds | 诺华股份有限公司 | 2022-06-24 | — | — | CN | disclosed |
| EP-3697788-B1 | BIS(PENTAHYDROXYHEXYL)AMINO SUBSTITUTED 2-{[(3-AMINO-PYRAZIN-2-YL)FORMAMIDO]METHYL}-1H-1,3-BENZODIAZOL-3-IUM DERIVATIVES AS ENAC INHIBITORS FOR TREATING RESPIRATORY DISEASES | ENTERPRISE THERAPEUTICS LTD (GB) | 2021-12-15 | — | — | EP | disclosed |
| EP-3888657-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | Incyte Holdings Corporation (US) | 2021-10-06 | — | — | EP | disclosed |
| WO-2007031428-A1 | 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-22 | — | — | WO | disclosed |
| WO-2007025776-A2 | CYSTEINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007017092-A1 | SUBSTITUTED 4-BENZYLOXY-BENZOIC ACID AMIDE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2007-02-15 | — | — | WO | disclosed |
| EP-1702916-A1 | DPP-IV inhibitors | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2006-09-20 | — | — | EP | disclosed |
| EP-0422996-B1 | Liquid crystal compound | SHOWA SHELL SEKIYU (JP) | 1995-04-12 | — | — | EP | disclosed |
| US-5328641-A | Naphthalene ester derivatives with trifluoromethyl groups | SHOWA SHELL SEKIYU KABUSHIKI KAISHA | 1994-07-12 | — | — | US | disclosed |
| US-5207947-A | Trifluoroalkyl diaryl triesters; antiferroelectricity; electrooptics | SHOWA SHELL SEKIYU KABUSHIKI KAISHA (JP) | 1993-05-04 | — | — | US | disclosed |
| EP-0422996-A2 | Liquid crystal compound | Showa Shell Sekiyu Kabushiki Kaisha (JP) | 1991-04-17 | — | — | EP | disclosed |
| US-4139381-A | DIFFUSION TRANSFER, ANTIFOGGING AGENTS | POLAROID CORPORATION (US) | 1979-02-13 | — | — | US | disclosed |
| US-4088499-A | METHYLENE GROUP CONTAINING POLYMERS | EASTMAN KODAK COMPANY (US) | 1978-05-09 | — | — | US | disclosed |